drugset
drugset / Trial / NCT03175835

Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects

NCT03175835 ↗

Phase 1 Completed 30 enrolled Chong Kun Dang Pharmaceutical
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the drug interaction between CKD-519 and rosuvastatin in healthy male subjects.

Timeline

Start
2017-05-08
Primary completion
2017-06-19
Completion
2017-06-19

Drugs

EvaluationDrugModalityDoseRoute
Subject ROCACETRAPIB Small molecule 200 mg —
Subject Rosuvastatin Small molecule 20 mg —

Indications

hyperlipidemia